Balversa Fast-Tracked for Bladder Cancer

Erdafitinib is first targeted therapy for FGFR3 or FGFR2 genetic alteration.

Source: CancerNetwork - April 12, 2019 Category: Cancer & Oncology Authors: David Frabotta Source Type: news